Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ALKS
ALKS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ALKS News
Alkermes 2026 Financial Outlook and Acquisition Progress
Feb 25 2026
seekingalpha
Alkermes Reports Decline in Q4 Earnings
Feb 25 2026
NASDAQ.COM
Alkermes Reports 2025 Financial Results and 2026 Outlook
Feb 25 2026
Newsfilter
Alkermes Q4 Earnings Report Analysis
Feb 25 2026
seekingalpha
Alkermes Set to Announce Q4 Earnings on February 25
Feb 24 2026
seekingalpha
Key Wall Street Rating Changes Overview
Feb 24 2026
CNBC
Wall Street Analysts Adjust Ratings
Feb 20 2026
Benzinga
Alkermes Acquires Avadel to Expand Product Portfolio
Feb 12 2026
Newsfilter
Goldman Sachs Downgrades Super Micro Computer to Sell with $26 Price Target
Jan 20 2026
Benzinga
ImmunityBio (IBRX) Shares Surge 39.8% on Positive QUILT-106 Study Data
Jan 19 2026
NASDAQ.COM
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton, Potentially Accelerating Development
Jan 19 2026
Yahoo Finance
Super Micro Computer Rated Sell, Medline Rated Buy by Analysts
Jan 17 2026
CNBC
Guess, NESR, and Alkermes Rated Buy with Strong Value Characteristics
Jan 14 2026
NASDAQ.COM
Avadel Pharmaceuticals Shareholders Approve Alkermes Buyout
Jan 12 2026
Yahoo Finance
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton in Treating Narcolepsy Type 1
Jan 06 2026
NASDAQ.COM
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton in Treating Narcolepsy Type 1
Jan 06 2026
Newsfilter
Show More News
